Celator Pharmaceuticals Inks $32.5M in New Funding
Celator Pharmaceuticals Inc., clinical-stage biopharmaceuticals company focused on cancer treatment, has raised US$32.5 million in the final closing of a private placement of common stock and warrants to purchase common stock. The deal was led by U.S. venture capital firm Valence Life Sciences. Celator, which has offices in Vancouver and Princeton, New Jersey, has been venture-backed since 2002. Its other investors include BDC Venture Capital, Domain Associates, GrowthWorks, Hearthstone Investment, Quaker BioVentures, TL Ventures and Ventures West Capital.
1 May 2013•4 mins read
